摘要
目的探究尼妥珠单抗+顺铂行同期放化疗对鼻咽癌患者预后生存质量的影响。方法方便选取2021年5月—2023年5月常熟市第一人民医院肿瘤科收治的68例鼻咽癌患者作为研究对象,依据不同治疗方法分为对照组、观察组,各34例。对照组接受顺铂同期放化疗治疗,观察组在对照组基础上联合尼妥珠单抗治疗,比较两组患者临床疗效,生活质量以及不良反应发生率。结果观察组治疗总有效率为64.71%(22/34),高于对照组的38.23%(13/34),差异有统计学意义(χ2=4.769,P<0.05)。治疗前,两组患者生活质量评分比较,差异无统计学意义(P>0.05);治疗后,观察组生活质量评分高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组白细胞计数为(5.11±0.44)×109/L,高于对照组的(3.74±0.35)×109/L,差异有统计学意义(t=14.208,P<0.05)。结论尼妥珠单抗+顺铂行同期放化疗方案用于鼻咽癌患者可改善患者生活质量,并提高治疗有效率,不良反应较少。
Objective To explore the effects of concurrent chemoradiotherapy with nituzumab plus cisplatin on the prognosis and quality of life of patients with nasopharyngeal carcinoma.Methods A total of 68 nasopharyngeal carcinoma patients admitted to the Oncology Department of the First People's Hospital of Changshu City from May 2021 to May 2023 were conveniently selected as the study objects,and were divided into control group and observation group according to different treatment methods,with 34 cases in each group.The control group received concurrent chemoradiotherapy with cisplatin,and the observation group was combined with nituzumab on the basis of the control group.The clinical efficacy,quality of life and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 64.71%(22/34),which was higher than that of the control group 38.23%(13/34),and the difference was statistically significant(χ2=4.769,P<0.05).Before treatment,there was no significant difference in quality of life scores between the two groups(P>0.05);after treatment,the life quality score of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).After treatment,the leukocyte count in the observation group was(5.11±0.44)×109/L,which was higher than that in the control group(3.74±0.35)×109/L,and the difference was statistically significant(t=14.208,P<0.05).Conclusion The concurrent chemoradiotherapy with nituzumab plus cisplatin can improve the quality of life of patients with nasopharyngeal carcinoma,and increase the effective rate of treatment with less adverse reactions.
作者
王鹰
WANG Ying(Department of Oncology,The First People's Hospital of Changshu City,Changshu,Jiangsu,215500,China)
出处
《中外医疗》
2024年第32期83-86,共4页
China & Foreign Medical Treatment
关键词
尼妥珠单抗
顺铂同期放化疗
鼻咽癌
生存质量
有效率
不良反应
Nituzumab
Concurrent chemoradiotherapy with cisplatin
Nasopharyngeal carcinoma
Quality of life
Efficient
Adverse reaction
作者简介
王鹰(1981-),女,硕士,副主任医师,研究方向为肿瘤内科治疗工作。
